William Blair Has Optimistic Outlook of CTNM Q3 Earnings

Key Points

• William Blair analysts have raised their Q3 2025 earnings per share estimate for Contineum Therapeutics from ($0.42) to ($0.35), maintaining an "Outperform" rating on the stock.
• Current consensus for Contineum Therapeutics' full-year earnings stands at ($2.01) per share, with the average price target from analysts set at $22.50.
• The company's stock has fluctuated recently, with a twelve-month low of $3.35 and a high of $20.55, currently trading around $6.73.

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) - William Blair upped their Q3 2025 EPS estimates for Contineum Therapeutics in a note issued to investors on Wednesday, August 6th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.42). William Blair has a "Outperform" rating on the stock. The consensus estimate for Contineum Therapeutics' current full-year earnings is ($2.01) per share. William Blair also issued estimates for Contineum Therapeutics' Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($1.25) EPS and FY2029 earnings at ($1.12) EPS.

Several other equities research analysts also recently commented on the stock. Royal Bank Of Canada reiterated an "outperform" rating and set a $31.00 price objective on shares of Contineum Therapeutics in a research note on Thursday, May 15th. Morgan Stanley decreased their target price on shares of Contineum Therapeutics from $25.00 to $20.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $22.50.

Contineum Therapeutics Trading Down 3.9%

Shares of CTNM stock traded down $0.26 during trading hours on Friday, reaching $6.47. 183,759 shares of the company's stock were exchanged, compared to its average volume of 321,049. Contineum Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $20.55. The stock's 50 day moving average is $4.68 and its 200-day moving average is $5.63. The company has a market cap of $167.39 million, a price-to-earnings ratio of -2.94 and a beta of 1.04.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06).

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CTNM. Strs Ohio acquired a new position in shares of Contineum Therapeutics in the first quarter worth about $27,000. Legal & General Group Plc raised its position in shares of Contineum Therapeutics by 74.0% in the fourth quarter. Legal & General Group Plc now owns 3,631 shares of the company's stock worth $53,000 after acquiring an additional 1,544 shares during the period. Corebridge Financial Inc. raised its position in shares of Contineum Therapeutics by 73.1% in the fourth quarter. Corebridge Financial Inc. now owns 5,215 shares of the company's stock worth $76,000 after acquiring an additional 2,202 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Contineum Therapeutics by 90.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company's stock worth $86,000 after acquiring an additional 2,783 shares during the period. Finally, Nuveen LLC acquired a new position in shares of Contineum Therapeutics in the first quarter worth about $93,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).